Hope Givers: New Book Inspires Strength and Healing Through Grief and Adversity
'Hope Givers will show you how to cope with challenging situations and gain hope. Most importantly, it will show you how to help others gain hope as well.' — Jack Tatar, co-author of Cryptoassets
TITUSVILLE, NJ, UNITED STATES, February 14, 2025 / EINPresswire.com / -- When facing adversity, hope is often found in the people who lift us up—those hope givers who provide comfort, connection, and encouragement in our most difficult moments. After losing her husband to ALS, author, TEDx speaker, and nonprofit founder Jodi O'Donnell-Ames experienced firsthand the power of hope givers in her own healing journey.
Now, in her inspiring new book, Hope Givers: Conversations and Stories of Hope, O'Donnell-Ames shares deeply personal insights and powerful conversations with thought leaders, mental health professionals, and individuals who have found resilience through life's most challenging moments.
'At a time when many are struggling with grief, uncertainty, and life's difficulties, Hope Givers offers real stories and tools to navigate hardship with strength and clarity,' says O'Donnell-Ames. 'It's an indisputable truth that while life is complicated and difficult, hope is reserved for each and every one of us.'
A Personal Journey to Helping Others
After her husband Kevin O'Donnell passed away from ALS at just 36 years old, O'Donnell-Ames dedicated her life to supporting families affected by terminal illness and adversity. She founded Hope Loves Company, the only nonprofit dedicated to supporting the children and grandchildren of ALS patients.
During the COVID-19 pandemic, she launched the podcast Gratitude to Latitude: Stories of Hope and Resilience, where she interviewed inspiring individuals about their journeys through adversity. This experience led to the creation of Hope Givers, a book that combines personal memoir, expert insights, and stories of resilience to help others navigate grief, loss, and personal growth.
The Power of the C.H.A.N.G.E. Method
In Hope Givers, O'Donnell-Ames introduces readers to the C.H.A.N.G.E. method, a framework designed to help individuals shift their mindset, embrace resilience, and find strength through life's transitions.
The book provides a raw, unfiltered look at overcoming grief and finding clarity, blending real-life experiences with actionable steps for emotional healing.
'Somewhere among these pages, you will find a moment of connection and insight,' she says. 'There are people and resources out there that will support you in your journey and help you process what you're feeling. Hope Givers is one of those resources.'
Praise for Hope Givers
Leaders in psychology, business, and personal development have praised Hope Givers for its heartfelt wisdom:
📖 'Hope Givers will show you how to cope with challenging situations and gain hope. Most importantly, it will show you how to help others gain hope as well.'
— Jack Tatar, co-author of Cryptoassets: The Innovative Investor's Guide to Bitcoin and Beyond
📖 'Written from the heart, this memoir highlights the transformative value of learning from others when dealing with grief. Honest, compassionate, and inspirational.'
— Fred Weber, Founder of Weber Scientific, SCORE Mentor
📖 'Despite hardships, Jodi provides empathy, perspective, and wisdom in seeking hope amid grief. She embodies turning pain into purpose.'
— Betsy Piccolo, LPC
Availability & Additional Information
Hope Givers: Conversations and Stories of Hope will be available May 10, 2024, on Amazon.
For more information, visit www.joaspeakson.com or connect with Jodi O'Donnell-Ames on:
📍 Facebook: [jodi.odonnellames]
📍 Instagram: [@jodi_odonnellames]
📍 Twitter/X: [@jodonnellames]
📍 LinkedIn: Jodi O'Donnell-Ames
Jodi L. ODonnell
JOA SPEAKS ON, INC.
+1 609-280-1905
X
Legal Disclaimer:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
China is catching up to the US in brain tech, rivaling firms like Elon Musk's Neuralink
'I want to eat' popped up in Chinese characters on a computer at a public hospital in central Beijing. The words were formed from the thoughts of a 67-year-old woman with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, who is unable to speak. The demonstration, captured on video in March by Beijing Radio and Television Station, was part of a clinical trial involving five patients implanted with a coin-sized chip called Beinao-1, a wireless so-called brain computer interface (BCI) – a technology led by scientists in the US, but in which experts say China is quickly catching up. Luo Minmin, director of the Chinese Institute for Brain Research (CIBR) and the chief scientist behind the trial, said there was a 'very strong' need for BCI technology, saying they had been 'overwhelmed' by requests from potential patients. 'The patients were saying that this feels so great, like they can gain or regain the control of (their) muscles,' he told CNN in May during a rare interview at his lab, located an hour's drive away from Beijing Xuanwu Hospital, where the trial took place. Luo said the technology was showing 'high accuracy' in decoding signals from the brains of patients and translating the signals into text speech or machine movements. His team is planning to speed up human trials by implanting chips into 50 to 100 more patients over the next year. 'We are hoping that we can move this process faster,' he said. 'If it's proven to be safe and effective … it can be used clinically across the world.' As of May, Beinao-1 says a total of five patients, the same number as Elon Musk's Neuralink, has its implants. Another US company Synchron, whose investors include Jeff Bezos and Bill Gates, has undergone trials with 10 patients, six in the United States and four in Australia. Maximilian Riesenhuber, a professor of neuroscience at Georgetown University who was not involved in the Beinao trials, told CNN that despite starting later than the US, China is making advances. 'China has definitely shown the ability to not just catch up, but also then be competitive, and now actually to start, also to drive the field in some areas,' he said. 'Excitingly, there's a lot of research activities in both countries, because they've realized the potential in BCI.' According to Precedence Research, a market research firm, the market for brain technology was worth about $2.6 billion last year and is expected to rise to $12.4 billion by 2034. But for both China and the US, this technology is about much more than cash. Chinese leader Xi Jinping has long aimed to turn his country into a science and economic powerhouse. In March, he wrote in state-owned media that the tech industry had become the 'forefront' and 'main battlefield' of global competition. His ambitions have sparked concern in the US, resulting in an ongoing tech war, particularly in the semiconductor industry. A different approach CIBR was jointly founded by the Beijing municipal government and several local universities in 2018, about two years after Elon Musk founded Neuralink near San Francisco. In 2023, CIBR incubated a private company named NeuCyber NeuroTech to focus on brain tech products such as Beinao-1. Luo, who is also the startup's chief scientist, gave CNN rare access to the institute in May. For years, he said, the ALS patient, who is in her 60s, was unable to express herself. 'She's awake, she knows what she wants but she could not speak out,' said the scientist, who got his PhD in neuroscience from the University of Pennsylvania and spent nearly a decade in the US. 'Following the implantation, she can now speak simple sentences quite accurately via the system.' All BCI researchers must address the balance between risk and effectiveness. Riensenhuber said most American firms use the more invasive method to place chips inside the dura mater, an outer layer of tissue that covers and protects the brain and spinal cord, in order to capture better signal. But these methods require riskier surgeries. 'It is interesting to see that NeuCyber is apparently able to get enough information even through the dura to allow the decoding of specific words,' he said. The test on the ALS patient, which began in March, marked the Beinao-1 chip's third trial in humans. Those trials made up what the developers described in a press release as 'the world's first batch of semi-invasive implantation of wireless BCI in human brains.' As of May, two more trials have been conducted, for a total of five. Clear ambition Amid rising geopolitical tensions, comparisons between US and Chinese tech breakthroughs are common. Brain computer interface technology first started in the 1970s in the US. Decades later, the Obama Administration launched its 'Brain Initiative' in 2013, investing more than $3 billion to fund over a thousand neuroscience technology projects since, according to the National Institute of Health. Synchron, based in New York, was the first firm to start human trials in July 2021. Three years later, a new BCI system developed at UC Davis Health translated the brain signals of an ALS patient into speech, achieving an accuracy of 97% – the most accurate system of its kind, the university said in a statement. The same year, Musk's company completed its first human trial, enabling the participant to control a computer mouse with a brain implant. China got its start in brain tech only in the 1990s, but it's advancing fast. In 2014, Chinese scientists introduced the idea of a national project on brain tech to match similar efforts in the US and Europe, according to the Ministry of Science and Technology. Two years later, brain tech was mentioned in the country's five-year plan, which outlines China's national priorities and goals. 'Brain science is new in China,' said Lily Lin, a former research assistant at one of China's top neuroscience research units from 2021 to 2023. 'So, it started a bit late, but its speed of development has been faster than other countries. And the country has given a lot of funding to many scientific research units, and this funding is increasing every year.' Last year, the government issued its first ethical guidelines for research in this area. At the local level, municipal governments in Beijing, Shanghai and other major cities have also offered support for brain technology companies from research and clinical trials to commercialization. Riesenhuber and other researchers from Georgetown University published research on China's BCI development in 2024, stating that efforts from Chinese researchers were 'comparable in sophistication' to those in the US and the United Kingdom. 'We found China's non-invasive BCI research to be comparable with that of other scientifically advanced nations and to be working to overcome obstacles to greater fidelity, throughput, and wider use,' according to the issue brief. 'China's invasive BCI research, while historically behind its non-invasive efforts, has picked up the pace and is approaching global standards of sophistication.' Luo, who has worked in both countries, says the US is the 'front-runner' in both invasive and non-invasive brain tech. But, comparing Beinao-1 and Neuralink is like looking at 'apples and oranges,' he added. The two systems differ not only in implant location but also in the type of brain signals recorded, as well as the method of data transmission. The Chinese chip records a wider range of brain areas, with lower precision for each neuron. 'All in all, I don't think these two products are in a competitive or exclusive relationship,' Luo added. 'The jury is still out, and we don't know yet which route will ultimately benefit patients better.' CNN's Joyce Jiang contributed to this report.
Yahoo
9 hours ago
- Yahoo
21-year-old MIT dropouts raise $32M at $300M valuation led by Insight
Karun Kaushik and Selin Kocalar weren't planning to raise a Series A so soon. Their AI compliance startup, Delve, which announced a $3 million seed round in January, was growing fast and signing customers at a steady clip. Then, inbound interest started rolling in, COO Kocalar told TechCrunch. Delve, which automates regulatory compliance with AI agents, ended up fielding multiple term sheets, eventually closing a $32 million Series A at a $300 million valuation. The round was led by Insight Partners, which took up most of the round, with participation from CISOs at Fortune 500 companies. Insight has been 'amazing to work with, and we felt they were the right long-term partner for us,' said the COO. Delve's new valuation represents a roughly 10x jump from its previous round. Similarly, its customer base has grown from the 100 companies it reported back in January to over 500, many of them fast-growing AI startups like recently minted AI unicorn Lovable, Bland, and Wispr Flow. And while the 2-year-old company, made up of AI researchers from MIT, Stanford, and Berkeley, has seemingly struck gold by using AI to eliminate hundreds of hours of manual processes, its story began much differently. Kaushik and Kocalar met as classmates during their freshman year at MIT. Both had deep interests in AI and health tech. Kaushik had already scaled a COVID diagnostic system to thousands of users during the pandemic. In 2023, they began working on an AI-powered medical scribe to help doctors handle patient documentation. However, handling sensitive healthcare information meant they quickly encountered the costly and time-consuming world of HIPAA compliance. Instead of continuing with the medical scribe, they started building tools to help other companies get HIPAA-compliant faster and more affordably. That pivot got the team into Y Combinator last year and helped them raise their seed round from General Catalyst, FundersClub, Soma Capital, and others. The founders dropped out during their sophomore year in 2023. What started with HIPAA quickly expanded. 'As our customer base grew, they started asking for support with other frameworks: SOC 2, PCI, GDPR, ISO, basically the whole alphabet soup of compliance,' Kocalar narrated. Compliance paperwork can be necessary in everything from launching products to closing enterprise deals. But instead of driving growth, its manual work can become a bottleneck. 'Compliance frameworks are standardized. Businesses aren't,' says CEO Kaushik. 'That mismatch is why traditional software breaks down and teams fall back to duct-taped workflows across email, Slack, and shared drives.' Delve replaces that busywork with AI agents that run in the background (after integrating with customers' tools) like internal team members. These agents collect evidence, write reports, update audit logs, and track configuration changes across fragmented systems, automating compliance workflows in real time. Kocalar says compliance is just the wedge into broader back-office operations. Long-term, the AI startup wants to automate a billion hours of other work — eventually expanding into adjacent areas like cybersecurity, risk, and internal governance. Insight Partners' interest reflects this roadmap. 'Since compliance touches every part of how a business runs, from scaling operations to closing deals to building customer trust, modernizing this function will modernize the entire organization,' said Praveen Akkiraju, managing director at Insight. 'That's what makes Delve's approach so important.' Still, the startup won't be without competition. Several AI companies are emerging with agents to automate business workflows. In addition, larger AI labs like OpenAI are releasing general-purpose agents capable of performing complex tasks. That said, Kocalar says these developments are a validation, not a threat, to Delve's business. She points to the company's domain depth in contrast to more general-purpose agents. 'We're positioning ourselves to improve as AI advances and labs roll out more sophisticated agentic technologies. But what truly sets us apart is the deep, domain-specific knowledge we're building into the platform,' she said. 'Compliance is always shifting as new regulations emerge and existing ones evolve, with companies interpreting them in different ways. That's where Delve stands out.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
USA Today
16 hours ago
- USA Today
See where COVID cases are rising amid summer wave: New CDC data
New data from the Centers for Disease Control and Prevention shows activity of COVID-19 is increasing across a wide swath of the country. As the U.S. approaches the midpoint of summer, the CDC is reporting cases of the virus are growing or likely growing in more than half of all states, including many in the South and Southeast. The center's July 18 report shows at least 26 states plus Washington, D.C., are encountering a summer surge, according to its epidemic trend modeling, using data from emergency department visits. The CDC notes its modeling indicates trends in overall cases, not the actual numbers of current infections. New COVID variant is spreading: What are the symptoms? A familiar summer surge The rate of positive COVID-19 tests is increasing nationally, the CDC said of the last week in data, with emergency department visits for the virus are increasing among children 4 years old and younger. Though there is an uptick in COVID-19 cases in more than two dozen states, the CDC says the overall amount of people seeking care for acute respiratory illnesses is at a very low level. That's accompanied by low levels of seasonal influenza activity and very low levels of RSV activity, the CDC says. Overall, trends in COVID-19 cases continue downward as compared to the last few years, according to long-term data trends in deaths, emergency room visits and positive cases. The U.S. has seen a wave of higher COVID-19 cases every summer since 2020. COVID-19 in 2025: What's the latest vaccine guidance? It's complicated. COVID-19 cases are growing in 10 states: The CDC's latest report says cases are likely growing in more than a dozen other states, plus Washington, D.C. In one state − Montana − COVID-19 cases are likely declining. COVID-19 cases are likely growing in the following 16 states: Kathryn Palmer is a national trending news reporter for USA TODAY. You can reach her at kapalmer@ and on X @KathrynPlmr.
